Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DARATUMUMAB Cause Cardiac failure congestive? 82 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 82 reports of Cardiac failure congestive have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.3% of all adverse event reports for DARATUMUMAB.

82
Reports of Cardiac failure congestive with DARATUMUMAB
0.3%
of all DARATUMUMAB reports
21
Deaths
53
Hospitalizations

How Dangerous Is Cardiac failure congestive From DARATUMUMAB?

Of the 82 reports, 21 (25.6%) resulted in death, 53 (64.6%) required hospitalization, and 16 (19.5%) were considered life-threatening.

Is Cardiac failure congestive Listed in the Official Label?

Yes, Cardiac failure congestive is listed as a known adverse reaction in the official FDA drug label for DARATUMUMAB.

What Other Side Effects Does DARATUMUMAB Cause?

Plasma cell myeloma (2,980) Infusion related reaction (2,557) Off label use (2,494) Pneumonia (1,450) Neutropenia (1,351) Drug ineffective (1,110) Thrombocytopenia (1,089) Death (1,088) Pyrexia (1,032) Dyspnoea (996)

What Other Drugs Cause Cardiac failure congestive?

ROSIGLITAZONE (15,085) METFORMIN\ROSIGLITAZONE (1,408) LENALIDOMIDE (1,373) AMBRISENTAN (1,359) SACUBITRIL\VALSARTAN (1,355) APIXABAN (1,144) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (1,129) AVANDIA (1,102) ADALIMUMAB (990) MACITENTAN (979)

Which DARATUMUMAB Alternatives Have Lower Cardiac failure congestive Risk?

DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ DARATUMUMAB vs DARBEPOETIN ALFA DARATUMUMAB vs DARIDOREXANT DARATUMUMAB vs DARIFENACIN HYDROBROMIDE DARATUMUMAB vs DAROLUTAMIDE

Related Pages

DARATUMUMAB Full Profile All Cardiac failure congestive Reports All Drugs Causing Cardiac failure congestive DARATUMUMAB Demographics